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The advances in biotechnology as applied to malignant
disease, and to breast cancer in particular, have been
astonishing over recent years. In the present section, four
approaches of contemporary interest and importance were
evaluated – particularly in relation to their potential for
impacting on clinical management of the disease.
Circulating tumour cells are detected in more than one-half of
patients with advanced breast cancer, and their prognostic
significance above a threshold of five cells per sample has
been clearly demonstrated in this setting. It is not yet clear
whether this provides major benefits for management of the
disease – but the potential for these cells to act as a material
for biomarker assessment in trials of new therapeutics is
substantial and is already being met in prostate cancer. In
primary breast cancer the data are less compelling, with far
fewer cells being found, providing a challenge for repro-
ducible measurements in individuals. It is possible that
noncellular markers in blood, particularly of circulating DNA,
may act as improved markers of residual disease. The
characterisation of DNA in an individual’s tumour to identify
specific aberrations and the use of that profile to create
specificity to DNA in blood is an approach that is highly
attractive and may become feasible in a few years as the
comprehensive characterisation of tumour DNA becomes
more affordable and sufficiently rapid (see below).
Over the past decade the greatest amount of biological
investigation has been related to the RNA profiling of breast
tumours. Seminal publications identifying so-called intrinsic
subtypes have substantially influenced thinking about breast
cancer subtypes. It is now widely agreed that this approach
identified an important new set of tumours – described as
basal tumours – which overlaps substantially with, but is not
identical to, triple-negative tumours. Luminal A and luminal B
subgroups of oestrogen receptor-positive tumours have also
been described, but the separation of these two groups is
much less defined with the biology being largely a continuum
from low proliferative luminal A tumours to highly proliferative
luminal B tumours. Many further signatures have been derived
from the profiling of other sets of tumours, and some have
resulted in the derivation of clinically applied multigene
parameters – such as the Oncotype DX 21-gene score, and
the Mammaprint 70-gene profile. Given the expenditure on
these parameters, it is important that they now be compared
with standard immunohistochemical approaches combined
with classical clinical pathological features. RNA profiling is
likely to be most valuable when it is applied thoughtfully to the
assessment of specific bioclinical questions.
It is widely accepted that aberrations in DNA are the driving
force behind malignancies. Technologies for assessing these
have improved through a number of steps, such as
comparative genomic hybridisation, both classical and array
based, but the power of new/next-generation sequencing to
identify essentially all differences between germline and
tumour genotypes will provide enormous challenges.
Harnessing the vast amount of data derived into meaningful
information that can be linked to the biology and clinical
outcome of tumours will be predictably problematic. While
the $1,000 genome is probably only a few years away, and
this would make sequencing of DNA across tumours
affordable, to create enormous catalogues of genomic
information without giving substantial thought to study design
is likely to be frustrating and of limited value.
The last presentation in this section (not reported fully in the
present supplement) reports not just the use of protein
changes using novel protein-based microarrays but also the
integration of these changes with RNA and DNA analyses.
Superficially this might be expected to complicate the linkage
of data to clinical outcome yet further, given that even more
aberrations will be identified. The key, however, is in the word
integration – such that this should allow the significance of an
aberration in one cellular fraction to be confirmed or refuted
in another, and in particular functionality of the change to be
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established. This allows potential driver abnormalities to be
distinguished from passengers. In addition, the linkage of
such work to the cell line as well as tumours provides a
greater opportunity to identify important biological processes
and pathways as opposed to individual genes.
In conclusion, these technologies hold great promise for the
future – but it is important that they should be applied
thoughtfully to well-annotated clinical materials: to achieve
the greatest value in clinical applicability.
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